These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 11222403)
1. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403 [TBL] [Abstract][Full Text] [Related]
2. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431 [TBL] [Abstract][Full Text] [Related]
3. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038 [No Abstract] [Full Text] [Related]
4. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Barbey JT; Pezzullo JC; Soignet SL J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391 [TBL] [Abstract][Full Text] [Related]
5. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058 [TBL] [Abstract][Full Text] [Related]
6. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Barbey JT; Soignet S Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116 [No Abstract] [Full Text] [Related]
11. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595 [TBL] [Abstract][Full Text] [Related]
12. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292 [TBL] [Abstract][Full Text] [Related]
13. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. Ducas RA; Seftel MD; Ducas J; Seifer C J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914 [TBL] [Abstract][Full Text] [Related]
14. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles. Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962 [TBL] [Abstract][Full Text] [Related]
15. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272 [No Abstract] [Full Text] [Related]
16. Arsenic trioxide and olanzapine co-administration: case analysis. Kaufman KR; Chhabra S; Levitt M; Sood R J Oncol Pharm Pract; 2011 Sep; 17(3):260-4. PubMed ID: 20015926 [TBL] [Abstract][Full Text] [Related]
17. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. Cashin R; Burry L; Peckham K; Reynolds S; Seki JT Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343 [TBL] [Abstract][Full Text] [Related]
18. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392 [TBL] [Abstract][Full Text] [Related]